It’s 2:00 a.m. in the ER, and a weary doctor is about to miss a life-threatening aortic dissection—until an AI assistant pings her with a high-likelihood alert.

In this premiere episode, we explore how AI has evolved from a computer science side project into the "new boss" of healthcare and drug discovery.

We trace the journey from the early "toddler years" of IBM Watson to the 2021 "mic drop" of DeepMind’s AlphaFold2, which solved the 3D protein-folding puzzle that had baffled scientists for decades.

Discover how this breakthrough has unlocked structure-based drug design, allowing researchers to engineer molecules that fit protein targets like a key in a lock.

The results are no longer just hype: by 2023, 21 AI-developed drugs had already marched through Phase I clinical trials with an astonishing 80–90% success rate.

We look at pioneers like Insilico Medicine and Exscientia, who are slashing drug discovery timelines from years to months.

We also go inside modern hospitals, where over 220 FDA-authorized AI devices are now helping radiologists catch subtle micro-fractures and early-stage pneumonia.

While challenges like "Black Box" algorithms and data bias remain, the future points toward a "personalized collaboration" where AI sidekicks and real-time compound design become the new medical normal.